US Access & Evidence Shifts

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, health economist, and it's great to have you with us today.

SaraAnd I'm Sara, market access strategy. Always good to be here — and I'll say, I've had today's topics circled since this morning, particularly the Medicaid rebate piece.

MarcusSame here. We're looking at HCA's profit warning and what it signals for US healthcare access — that's a system-level stress test. Then the subcutaneous Leqembi approval and its HEOR implications — evidence strategy in the fast lane. The FTC settlement with CVS Caremark over insulin pricing — enforcement meets commercial reality. And CMS's proposed Medicaid rebate modifications — that could redefine manufacturer incentives.

SaraThat Medicaid rebate angle is fascinating to me — the budget impact there is one the field hasn't fully modeled yet, especially with dual eligibility complexities.

MarcusExactly. Let's get into it.

MarcusStarting with HCA's profit warning. This isn't just a financial alert; it's a canary in the coal mine for US hospital margins and, by extension, patient access. When major systems flag sustainability concerns, it cascades to formulary decisions and coverage policies. We're seeing pressure points in reimbursement models that could accelerate value-based contracting.

SaraThat's one read — but I'd frame it slightly differently. The part that gives me pause is how this intersects with Medicaid dual eligibles. If hospitals absorb uncompensated care, that directly impacts state budgets and CMS reimbursement rates. It's a budget impact multiplier effect that HEOR models aren't capturing yet.

MarcusFair point, though I think payers would see this as a structural issue rather than a temporary glitch. The real question is whether this forces HTA bodies to incorporate hospital financial health into coverage criteria. We've never had that before.

SaraWhat strikes me here is the operationalization challenge. How do you measure a hospital's 'sustainability' for coverage purposes? That's methodologically messy and precedent-setting. I keep coming back to whether this triggers a shift from pure clinical value to system-wide economic value.

MarcusThat connects to something I've been tracking — the CMS Innovation Center's hospital-focused pilots. This could be the catalyst for broader adoption. But I wonder if that's the full picture though. HCA's specific challenges might be idiosyncratic to their mix of services, not a universal trend.

SaraThat's fair — but the scale matters. When a system with this many facilities signals trouble, it creates ripples. The question is whether other systems follow suit, creating a de facto access barrier for high-cost drugs. That's where HEOR needs to pivot to hospital-level budget impact.

MarcusExactly. And from the payer side, it means anticipating reimbursement clawbacks if hospitals can't absorb costs. A complex feedback loop. Let's move to Leqembi.

SaraThe subcutaneous Leqembi approval is a pivotal moment for Alzheimer's evidence strategy. We're moving beyond traditional endpoints to real-world functionality measures, which aligns with FDA's accelerated approval flexibility. But the HEOR challenge is translating surrogate endpoints into meaningful value for payers.

MarcusI'd push back slightly on that framing. What's interesting here is the route to market — it's leveraging existing evidence while introducing a new administration method. That changes the value equation significantly. The cost of administration isn't trivial, and that affects the cost-effectiveness calculus.

SaraThat's true, but the part that gives me pause is the evidence generation timeline. We know from other neurodegenerative drugs that real-world evidence takes years to mature. How do payers justify coverage when the long-term outcomes data is still maturing? That's a classic evidence gap.

MarcusRight, and from the payer side, that creates uncertainty around budget impact projections. The question is whether CMS will use coverage with evidence development mechanisms, or if this forces a rethinking of the evidence threshold for high-need, high-cost therapies.

SaraThis is one of those stories where the methodology tension is acute. The FDA's focus on surrogate endpoints versus payers' demand for hard outcomes creates a misalignment. I keep coming back to whether this accelerates the use of RWE in coverage decisions, which has been slow to adopt.

MarcusThat's a key point — the operational hurdles for RWE in HTA are significant. But what's striking here is the precedent. If Leqembi's approval sets a new standard for leveraging real-world data in submissions, it could reshape the entire evidence landscape. Though I wonder if that's the full picture — the payer pushback on accelerated approvals remains strong.

SaraAbsolutely. And the cost implications are enormous. If this becomes the norm, we're talking about billions in potential spending with uncertain long-term benefits. That's a budget impact nightmare for health plans. Let's pivot to insulin pricing.

MarcusThe FTC settlement with CVS Caremark over insulin pricing is a watershed moment for enforcement mechanisms. It's not just about rebates; it's about transparency in how rebates are passed through to patients. This could fundamentally alter how manufacturers structure commercial contracts and how payers negotiate access.

SaraThat's one read — I'd frame it as a direct challenge to the pharmacy benefit manager (PBM) model. The FTC's focus on pass-through requirements means manufacturers might have to rethink rebate structures entirely. That could create new access pathways for biosimilars or lower-cost alternatives if PBMs can't extract the same margins.

MarcusFair point, though I think the industry would see this as regulatory overreach. The real question is whether this forces a shift from list-price negotiations to net-price transparency in coverage decisions. That would change the entire value proposition for new entrants.

SaraWhat strikes me here is the precedent for other therapeutic areas. If insulin is the test case, we could see similar actions in oncology or rare diseases. That would mean manufacturers have to build access strategies around FTC compliance, not just payer negotiations. A fundamental shift.

MarcusExactly. And from the payer side, it creates an opportunity to reallocate savings to other high-cost areas. But I wonder if that's the full picture though — will this actually reduce patient out-of-pocket costs, or will PBMs find new ways to capture value? That's the million-dollar question.

SaraThat's the operational uncertainty. The FTC's focus on pass-through is clear, but enforcement mechanisms are untested. We're in uncharted territory for commercial access strategy. This could force manufacturers to prioritize direct patient programs over rebate-driven contracts. Let's finish with Medicaid rebates.

SaraCMS's proposed Medicaid rebate modifications are arguably the most consequential policy shift in years. The potential changes to inflationary rebates and manufacturer fees could significantly alter the net-price landscape for high-cost drugs. This isn't just administrative; it's a structural shift in how manufacturers approach Medicaid pricing.

MarcusI'd push back slightly on the 'consequential' framing. What's interesting here is the timing — coming after the Inflation Reduction Act implementation. This could create a two-tiered system where Medicaid rebates become more punitive while Medicare negotiations proceed. That would force a complete reevaluation of lifecycle pricing strategies.

SaraThat's true, but the part that gives me pause is the budget impact uncertainty. If rebates increase, states face higher costs for dual eligibles. That could trigger formulary restrictions or utilization management, creating access barriers. The HEOR challenge is modeling these ripple effects across multiple stakeholders.

MarcusRight, and from the payer side, this creates a perverse incentive to shift costs to commercial plans. The question is whether CMS will address that in the final rule. We've seen similar issues with 340B pricing where unintended consequences dominate.

SaraThis is one of those stories where the methodology tension is acute. How do you balance manufacturer incentives with state budget realities? I keep coming back to whether this accelerates value-based contracting in Medicaid, which has been slow to adopt.

MarcusThat's a key point — the operational hurdles for VBAs in public programs are significant. But what's striking here is the precedent for other countries. If the US moves toward more dynamic rebate structures, it could influence global HTA frameworks. Though I wonder if that's the full picture — the industry pushback will be fierce.

SaraAbsolutely. And the access implications are enormous. If rebates become more punitive, manufacturers might delay launches or restrict access to Medicaid populations. That's a patient equity concern we haven't fully grappled with.

SaraA lot to think about today. I'll be watching how CMS finalizes the Medicaid rebate modifications and whether it triggers state-level formulary responses. That could be the next access battleground.

MarcusSame — and for me the thread running through today is the growing tension between regulatory enforcement and evidence-based access. We're seeing it with FTC actions, FDA approvals, and CMS policy shifts. Worth sitting with.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.